Notably, in a R/R CLL cohort treated with rituximab and IDELA, followed by open-label, single-agent IDELA, the presence of TP53 aberrations did not influence PFS (TP53 aberrations: median PFS 20.8 months versus wildtype: 18.8 months, HR 1.03; 95%CI, 0.62-1.72) (44). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.